EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer

Cisplatin-based chemotherapy is recommended as the primary treatment for advanced bladder cancer (BC) with unresectable or metastatic disease. However, the benefits are limited due to the acquisition of drug r...

Source: BMC Cancer - January 11, 2021 Category: Cancer & Oncology Authors: Shunsuke Okamura, Hirofumi Yoshino, Kazuki Kuroshima, Masafumi Tsuruda, Yoichi Osako, Takashi Sakaguchi, Masaya Yonemori, Yasutoshi Yamada, Shuichi Tatarano, Masayuki Nakagawa and Hideki Enokida Tags: Research article Source Type: research